Indan Journal of Medical Research Indan Journal of Medical Research Indan Journal of Medical Research
  Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login  
  Home Print this page Email this page Small font sizeDefault font sizeIncrease font size Users Online: 18156       
REVIEW ARTICLE
Year : 2020  |  Volume : 152  |  Issue : 5  |  Page : 456-467

Similar biologics in India: A story of access or potential for compromise?


1 Department of Rheumatology & Clinical Immunology, Vikram Hospital, Bengaluru, Karnataka, India
2 Department of Rheumatology, GD Hospital & Diabetes Institute, Kolkata, West Bengal, India
3 Department of Rheumatology, Madras Medical College, Chennai, Tamil Nadu, India
4 Department of Rheumatology, Max Super Specialty Hospital, New Delhi, India
5 Medical Affairs, Janssen, Johnson & Johnson Pvt. Ltd., Mumbai, Maharashtra, India

Correspondence Address:
Dr. Ramesh Jois
Department of Rheumatology & Clinical Immunology, Vikram Hospital, Millers Road, Bengaluru 560 052, Karnataka
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/ijmr.IJMR_43_18

Rights and Permissions

Biosimilars or similar biotherapeutic products are the biological products approved by regulatory agencies based on the demonstration of similarity in quality, safety and efficacy with reference biologics (or original biologics). Though biosimilars could be considered as interchangeable therapeutic alternatives over original biologics, there are concerns regarding their similarity in effectiveness and safety with reference product along with the level of evidence of similarity required for approval. The biosimilars, particularly, monoclonal antibodies that are developed based on the complex manufacturing processes, require stringent comparative evaluations. The Indian Regulatory Authorities in July 2012 developed the first guidelines for approval of similar biologics, which comprised requirements for the manufacturing process, quality evaluation, preclinical and clinical studies, as well as post-marketing studies. The 2016 guidelines, an update to previous guidelines, were released with the intent to provide a well-defined pathway at par with international regulations for the approval of similar biologics in India. This article highlights the key attributes of the 2016 Regulatory Guidelines and also describes the aspects such as interchangeability, nomenclature and labelling of similar biologics in India. Rigorous consideration is imperative for highly complex similar biologics of monoclonal antibodies on a case-to-case basis.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed782    
    Printed2    
    Emailed0    
    PDF Downloaded156    
    Comments [Add]    

Recommend this journal